- Home
- USEA vs SNTI Comparison
USEA vs SNTI Comparison
Compare USEA & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- SNTI
- Stock Information
- Founded
- USEA 2004
- SNTI 2016
- Country
- USEA Greece
- SNTI United States
- Employees
- USEA N/A
- SNTI N/A
- Industry
- USEA Marine Transportation
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- USEA Consumer Discretionary
- SNTI Health Care
- Exchange
- USEA Nasdaq
- SNTI Nasdaq
- Market Cap
- USEA 16.0M
- SNTI 17.8M
- IPO Year
- USEA N/A
- SNTI N/A
- Fundamental
- Price
- USEA $1.36
- SNTI $3.36
- Analyst Decision
- USEA Strong Buy
- SNTI Strong Buy
- Analyst Count
- USEA 1
- SNTI 1
- Target Price
- USEA $6.00
- SNTI $12.00
- AVG Volume (30 Days)
- USEA 73.1K
- SNTI 31.3K
- Earning Date
- USEA 03-18-2025
- SNTI 03-20-2025
- Dividend Yield
- USEA 16.43%
- SNTI N/A
- EPS Growth
- USEA N/A
- SNTI N/A
- EPS
- USEA N/A
- SNTI N/A
- Revenue
- USEA $45,439,000.00
- SNTI N/A
- Revenue This Year
- USEA $7.08
- SNTI N/A
- Revenue Next Year
- USEA N/A
- SNTI N/A
- P/E Ratio
- USEA N/A
- SNTI N/A
- Revenue Growth
- USEA 25.98
- SNTI N/A
- 52 Week Low
- USEA $1.34
- SNTI $1.52
- 52 Week High
- USEA $2.90
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- USEA 24.76
- SNTI 44.14
- Support Level
- USEA $1.40
- SNTI $3.33
- Resistance Level
- USEA $1.97
- SNTI $3.63
- Average True Range (ATR)
- USEA 0.10
- SNTI 0.34
- MACD
- USEA -0.03
- SNTI 0.01
- Stochastic Oscillator
- USEA 3.91
- SNTI 25.36
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.